Login to Your Account



Happy Holidays! FTC Gives More Oversight to Drugmakers

By Mari Serebrov
Washington Editor

Thursday, November 7, 2013
Just in time for the holidays, the FTC is gifting itself on the biopharma industry by finalizing a change to its premerger notification rule that makes transfers of “all commercially significant rights” to drug, biologic and in vitro diagnostic patents subject to antitrust review under the Hart Scott Rodino (HSR) Act.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription